"None of these headwinds can be faced without us bending. From my perspective, this move is a response to those changes, and it demonstrates our ability to be able to meet a challenge - it is important because it is going to continue," he told BioPharmaDispatch.
Dennis Bastas on Arrotex and creating the largest company by volume in PBS history
July 11, 2019 Latest NewsBioPharmaDispatch ExecutiveNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

